Glioblastoma Multiforme | sciencenewsnet.in

Breaking News

Magnetic Microcoils Unlock Targeted Single-Neuron Therapies for Neurodegenerative Disorders

Laser-Treated Cork Absorbs Oil for Carbon-Neutral Ocean Cleanup

Stress Activates Brain Regions Linked to Alcohol Use Disorder, Differently for Women Than Men

Tracy M. Valorie joins Glaucoma Research Foundation Board of Directors

Electro-Optic Tuning in Composite Silicon Photonics Based on Ferroionic 2D Materials

Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Medical Cannabis Certification Patterns for Chronic Pain

Green Bronx Machine Documentary “Generation Growth” Virtual Premiere – April 23, 2024 – 7 PM EST

Fields Medalist Pierre-Louis Lions Explores Mathematical Analysis and its Applications at CityUHK

AACN Publishes Standards for Appropriate Staffing in Adult Critical Care

23 Apr, 2024

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma

February 3, 2021 sarah JonasFeature

Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).